These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12230003)

  • 1. A simple technique to evaluate model sensitivity in the continual reassessment method.
    Cheung YK; Chappell R
    Biometrics; 2002 Sep; 58(3):671-4. PubMed ID: 12230003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The continual reassessment method in cancer phase I clinical trials: a simulation study.
    Chevret S
    Stat Med; 1993 Jun; 12(12):1093-108. PubMed ID: 8210815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of phase I cancer clinical trial designs.
    Ahn C
    Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.
    Møller S
    Stat Med; 1995 May 15-30; 14(9-10):911-22; discussion 923. PubMed ID: 7569510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pocrm: an R-package for phase I trials of combinations of agents.
    Wages NA; Varhegyi N
    Comput Methods Programs Biomed; 2013 Oct; 112(1):211-8. PubMed ID: 23871691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
    Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
    Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive design improvements in the continual reassessment method for phase I studies.
    Heyd JM; Carlin BP
    Stat Med; 1999 Jun; 18(11):1307-21. PubMed ID: 10399198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
    Liu S; Pan H; Xia J; Huang Q; Yuan Y
    Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical aspects of the Bayesian approach to phase I cancer trials.
    Neuenschwander B; Branson M; Gsponer T
    Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
    Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
    PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.
    Onar A; Kocak M; Boyett JM
    J Biopharm Stat; 2009; 19(3):437-55. PubMed ID: 19384687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
    Asakawa T; Hirakawa A; Hamada C
    J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.